Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) shares fell by 2.35% on Monday, closing at $115.04, despite a positive trading session for the broader market. This marks the third consecutive day of losses for the stock, while the S&P 500 Index and Dow Jones Industrial Average both saw gains. The article highlights Teleflex's underperformance relative to its competitors and the major market indices.
Teleflex Inc. stock: Steady in healthcare volatility?
Teleflex Inc. (TFX) is presented as a reliable investment in the volatile healthcare sector, focusing on essential medical devices for critical care and surgery. The company's B2B model and strong North American presence offer defensive growth, appealing to investors seeking stability rather than high-risk biotech plays. While facing risks like reimbursement pressures and supply chain issues, analysts view Teleflex as a solid hold due to its execution, margin expansion potential, and consistent dividend policy.
Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up
Teleflex (TFX) reported a Q1 earnings beat, with adjusted EPS of $2.93 exceeding estimates and net revenues of $727.6 million up 2.7% year-over-year. Despite the earnings beat, the company lowered its 2025 adjusted EPS guidance to a range of $13.60 to $13.90, primarily due to increased interest expenses, but raised its 2025 revenue outlook. The stock rose over 3% in pre-market trading following the announcement.
Wealth Enhancement Advisory Services LLC Has $3.62 Million Stake in Teleflex Incorporated $TFX
Wealth Enhancement Advisory Services LLC significantly reduced its stake in Teleflex Incorporated by 50% to $3.62 million, while other institutions, notably Greenhaven Associates, initiated new positions. Teleflex reported a substantial earnings and revenue miss for its latest quarter but provided FY2026 EPS guidance. Analyst sentiment for TFX is mixed, with a consensus "Hold" rating and an average price target of $139.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc.'s stock (TFX) rallied by 4.07% to $119.61 on Tuesday, outperforming the broader market. This strong performance occurred on a day when both the S&P 500 Index and the Dow Jones Industrial Average also saw significant gains. Despite the rally, Teleflex Inc. remains 15.71% below its 52-week high.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) shares dropped 1.11% on Monday, closing at $114.93, despite a mixed trading day for the broader market. This decline broke a five-day winning streak for the company's stock. The Dow Jones Industrial Average saw a slight gain, while the S&P 500 Index experienced a decline.
Teleflex Inc. Stock: Strategic Divestitures and Buybacks Signal Path to Shareholder Value Amid Chall
Teleflex Inc. (TFX) shares surged following announcements of $1.8 billion in divestitures to fund share buybacks and debt reduction, alongside operational improvements. The company aims to enhance shareholder value and address profitability pressures by streamlining its operations and focusing on high-growth areas. Investors are closely watching the execution of these strategic moves and potential earnings acceleration in 2027.
Teleflex Faces Activist Pressure On Board Decisions And Potential Sale Options
Activist investor Irenic Capital Management is pressuring Teleflex (NYSE:TFX) to consider acquisition offers, form a Strategic Review subcommittee with new independent directors, and address concerns about value destruction and leadership. This comes as Teleflex plans to sell non-core businesses for $1.8 billion to fund buybacks and debt reduction. The market is paying close attention to these developments, which could lead to a company sale or a sharper focus on shareholder returns.
Teleflex Shares Surge on Strategic Array of Corporate Actions
Teleflex Inc. (TFX) shares surged by 5.89% driven by an analyst upgrade to "Outperform" from Raymond James, a planned $1 billion share repurchase, and a restructuring program aiming for $50 million in annual cost savings. Despite some mixed financial fundamentals including negative profit margins, the company's strategic initiatives and strong technical indicators suggest potential for growth. The outlook is cautiously optimistic, contingent on successful execution of its plans to improve profitability and shareholder value.
Teleflex Stock Skyrockets After $1.8B Divestiture Plan and Share Buyback
Teleflex Incorporated's stock rose 5.89% after announcing a plan to divest $1.8 billion in assets for share repurchases and debt reduction, aiming to enhance shareholder value and streamline operations. Despite past financial challenges like negative equity and declining revenue, strategic moves and positive analyst ratings suggest a potential recovery. The company's stock broke resistance at $110, closing at $117, indicating strong purchasing momentum.
Vanguard disaggregates holdings; reports 0 shares in Teleflex (NYSE: TFX)
The Vanguard Group has filed a Schedule 13G/A amendment reporting 0 shares and 0% beneficial ownership of Teleflex (NYSE: TFX) common stock. This change is due to an internal realignment at Vanguard, where certain subsidiaries will now report their holdings separately in accordance with SEC Release No. 34-39538. Ashley Grim, Head of Global Fund Administration, signed the amendment on March 27, 2026.
Teleflex Stock Gains Amid Restructuring and Board Valuation Moves
Teleflex (TFX) stock gained 5.89% recently following an FDA clearance and news of strategic restructuring, including a $1 billion share buyback and $800 million debt reduction. Activist investor Irenic Capital has pushed for these changes due to poor shareholder returns. Raymond James upgraded the stock to Outperform, anticipating future earnings acceleration despite current profitability challenges.
Teleflex says Irenic falsely claimed company was not open for buyout offers
Teleflex (TFX) refuted claims by activist investor Irenic Capital, stating that the company has always been open to and has engaged in discussions regarding potential acquisitions or strategic alternatives. This comes after Irenic accused Teleflex of rejecting or ignoring several takeover bids. Teleflex highlighted its past acquisition of Vascular Solutions and its ongoing commitment to shareholder value.
Wedge Capital Management L L P NC Has $30.82 Million Position in Teleflex Incorporated $TFX
Wedge Capital Management L L P NC significantly increased its stake in Teleflex Incorporated, holding 252,547 shares valued at $30.82 million. This comes despite Teleflex reporting a substantial miss on earnings and revenue estimates, along with a negative net margin. The company is also facing strategic pressure from an activist investor and mixed analyst reactions, with some upgrades indicating potential upside from either operational improvements or strategic outcomes.
Assessing Teleflex (TFX) Valuation After Recent Share Price Rebound And High P/E Multiple
Teleflex (TFX) has experienced a recent rebound in its share price but still trades at a high P/E multiple. While its valuation narrative suggests it is 10.1% undervalued at $129.25 per share, its current P/E of 87.8x is significantly higher than industry averages, indicating potential valuation risk. Investors are advised to consider the risks associated with this high P/E and potential issues with products like UroLift or BIOTRONIK integration.
Teleflex (TFX) defends strategy with $1.8B sales, $1B buyback and restructuring push
Teleflex (TFX) is defending its strategic plan against Irenic Capital, emphasizing its focus on portfolio optimization, capital returns, and cost reductions. The company plans to sell its Acute Care, Interventional Urology, and OEM businesses for an expected $1.8 billion in after-tax net proceeds, which will fund a $1.0 billion share repurchase and $800 million in debt reduction. Additionally, Teleflex aims for approximately $50 million in annual pre-tax cost savings by mid-2028 through a multi-year restructuring plan.
Teleflex Moves Forward with o9 Solutions, Strategic Plans Shift Focus
Teleflex Incorporated's stock surged 4.38% after a strategic partnership with o9 Solutions and an FDA nod, despite facing challenges like declining revenue and low profit margins. The company is undergoing restructuring and divestitures to streamline growth, with analysts maintaining a hold consensus but seeing positive long-term prospects. While technical analysis shows a bullish trend, caution is advised due to integration risks.
Teleflex Investor Demands Sale After 73% Stock Decline
Irenic Capital Management, a major shareholder in Teleflex (2% stake), is urging the company's board to engage with potential acquirers after the stock experienced a 73% decline over five years. Irenic alleges that the board, which has long-tenured directors and minimal personal stock purchases, is actively refusing acquisition offers and concerns are widespread among shareholders. The firm believes the board's track record of value destruction disqualifies it from unilaterally determining the company's future without exploring all alternatives.
Irenic Capital calls on Teleflex board to form sub-committee with new independent directors
Irenic Capital has urged the Teleflex board to establish a sub-committee staffed with new independent directors. This call comes amidst ongoing discussions about potential sales deals for aspects of Teleflex's business, which the company states are on track to close in the second half of 2026. Teleflex has also clarified it has not rebuffed potential buyers, pushing back on Irenic's claims.
Irenic Comments on Teleflex’s Announcement That It Is Open to Strategic Alternatives
Irenic Capital Management, a major shareholder of Teleflex (TFX), welcomed the company's openness to strategic alternatives. Irenic suggested forming a Strategic Review sub-committee with new independent directors, including a shareholder representative, to oversee the process and maximize value. Irenic expressed disagreement with the Board's characterization of past conversations but looks forward to collaboration.
Activist investor urges Teleflex to explore sale, oust Stephen Klasko from chairman role
A major investor, Irenic Capital Management, is pushing Teleflex Inc. to consider selling the company and remove Stephen Klasko from his chairman role. Teleflex has responded by claiming Irenic Capital Management is "grossly mischaracterizing" Klasko's comments.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares surged 5.19% to $116.22 on Friday, contrasting with a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the fifth consecutive day of gains for Teleflex, showcasing its strong performance relative to competitors. The article highlights the stock's resilience during an otherwise poor trading session.
Activist Investor Urges Teleflex To Engage Potential Buyers
Activist investor Irenic Capital Management, holding a 2% stake in Teleflex, is pressuring the company's board to consider engaging with potential acquirers to boost shareholder value. The firm highlights a significant decline in shareholder returns over the past five years and criticizes the board's lack of open market stock purchases. Despite some short-term technical strength, Teleflex faces long-term weakness and weak rankings across value, growth, and momentum, according to Benzinga Edge.
Teleflex (NYSE:TFX) Shares Gap Up Following Analyst Upgrade
Teleflex (NYSE:TFX) shares gapped up after Raymond James upgraded the stock from "market perform" to "outperform" with a $128 price target. This upgrade comes despite the company reporting a significant earnings and revenue miss and issuing conservative FY2026 guidance. Analyst coverage for Teleflex is currently mixed, with institutional investors holding a large majority of the stock.
Irenic urges Teleflex to consider acquisition offers By Investing.com
Irenic Capital Management, holding a 2% stake in Teleflex Incorporated, has sent a letter to the medical device company's board urging them to engage with potential acquirers. Despite Teleflex's significant negative shareholder return over the past five years and its operation without a permanent CEO, Irenic claims multiple parties are interested in an acquisition. The activist investor is also calling for board changes, including a new chairman, to address the company's underperformance.
Teleflex Inc Stock: A Leader in Medical Devices Faces Strategic Shifts and Market Pressures in Healthcare
Teleflex Inc. is a prominent medical device company specializing in critical care, vascular access, and urology products. The company faces competitive healthcare markets but demonstrates resilience through strategic R&D and a focus on high-margin, single-use products, particularly in North America. Investors should monitor upcoming earnings, strategic initiatives, and market trends amid continued volatility and competitive pressures, balancing growth potential against valuation concerns.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 2.14% to $110.49 on a grim trading day where the S&P 500 and Dow Jones Industrial Average both fell. This marks the fourth consecutive day of gains for the stock. MarketWatch Automation, supported by Dow Jones and FactSet, reported on this performance.
Teleflex Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Teleflex Inc. (TFX) shares rose 1.52% to $108.18 on Wednesday, marking its third consecutive day of gains. Despite this increase, the stock underperformed compared to its competitors, even as the broader market indexes, such as the S&P 500 Index and the Dow Jones Industrial Average, also saw positive movement.
Teleflex Inc. stock faces pressure amid medical device sector slowdown and tightening hospital spend
Teleflex Inc. shares are experiencing pressure due to a slowdown in the medical device sector, driven by tightening hospital budgets, persistent inflation in healthcare costs, and intensifying FDA reviews on key vascular access products. US investors should be aware of these challenges impacting medtech margins and growth outlooks, especially given the company's significant reliance on North American hospital economics. Despite these headwinds, Teleflex exhibits resilience through innovation, a global footprint, and cost discipline, positioning it for potential recovery once hospital capital expenditures rebound.
Teleflex Inc. stock faces pressure amid medical device sector slowdown and regulatory scrutiny
Teleflex Inc. (ISIN: US8793691069) shares are under pressure due to a slowdown in the medical device sector, tightening hospital budgets, and increased FDA scrutiny, leading to a recent Q4 earnings miss. Despite these challenges, the company’s strong balance sheet and focus on minimally invasive technologies offer long-term potential for investors. The article details market reactions, regional exposure, product portfolio, competitive landscape, and key risks for the stock.
Teleflex Inc. stock faces valuation scrutiny amid multi-year decline and fresh institutional interes
Teleflex Inc. (NYSE: TFX) has experienced a significant multi-year stock decline, leading to debates about its valuation despite recent institutional interest from Greenhaven Associates. While some analyses suggest the stock is overvalued with a discounted cash flow intrinsic value of $69.32 against a market price around $105, analysts still project a modest 7.16% upside. The company is undergoing strategic initiatives, including a potential split into two entities, aimed at unlocking value and potentially driving a rebound in the medical devices sector.
122,079 Shares in Teleflex Incorporated $TFX Purchased by Greenhaven Associates Inc.
Greenhaven Associates Inc. has purchased 122,079 shares of Teleflex Incorporated (NYSE:TFX) worth approximately $14.9 million, making it the 17th largest holding in their portfolio. This investment comes despite Teleflex missing recent earnings expectations, reporting an EPS of $1.93 against an expected $3.73 and a significant revenue decline. The market currently holds a "Hold" consensus rating for Teleflex, with shares recently down about 1.6% and the company declaring a quarterly dividend.
Teleflex Inc. stock underperforms Friday when compared to competitors
Teleflex Inc. (TFX) shares underperformed on Friday, shedding 1.53% to close at $105.41. This decline occurred during a generally dismal trading session, with the S&P 500 Index falling 1.51% and the Dow Jones Industrial Average falling 0.96%. It marked the stock's fourth consecutive day of losses.
Teleflex Incorporated Files 8-K Announcing OEM Agreement with Lotus US Bidco Inc. and Provides Company Details
Teleflex Incorporated (NYSE: TFX) has filed an 8-K announcing an update on the divestiture of its Original Equipment Manufacturer (OEM) and Development Services business to Lotus US Bidco Inc., an affiliate of Montagu Private Equity LLP and Kohlberg & Co., L.L.C. This transaction is part of Teleflex's portfolio optimization strategy and is separate from its Acute Care and Urology Transaction. The company, headquartered in Wayne, PA, emphasizes that this move aims to streamline its business and may impact its future financial profile and share price.
Teleflex Inc. stock underperforms Wednesday when compared to competitors
Teleflex Inc. (TFX) stock fell 1.09% to $107.81 on Wednesday, underperforming the broader market. This occurred during a dismal trading session where the S&P 500 Index dropped 1.36% and the Dow Jones Industrial Average fell 1.63%. This marks the second consecutive day of losses for Teleflex Inc. stock.
Teleflex says HSR waiting period expired for OEM deal; FTC issues second request for Acute Care and Urology sale
Teleflex announced that the HSR waiting period for its OEM transaction expired on March 13, 2026, and this deal is expected to close in Q3 2026. However, the FTC issued a second request for information regarding the company's Acute Care and Urology transaction, extending its HSR waiting period. As a result, the Acute Care and Urology transaction is now anticipated to close in H2 2026.
Teleflex's acute care and urology purchaser received request for additional information & documentary material from U.S. FTC
Teleflex's acute care and urology purchaser has received a request for additional information and documentary material from the U.S. Federal Trade Commission (FTC). This development indicates heightened regulatory scrutiny regarding the transaction. The article also provides recent news affecting Teleflex Incorporated (TFX), including earnings reports, analyst rating adjustments, and dividend announcements.
Invenomic Capital Management LP Increases Holdings in Teleflex Incorporated $TFX
Invenomic Capital Management LP significantly increased its stake in Teleflex Incorporated (TFX) by 35.6% in Q3, making it their 6th largest holding. Despite this, Teleflex experienced a challenging quarter, missing earnings and revenue expectations, primarily due to a 28.5% year-over-year revenue decline. The company has also declared a quarterly dividend of $0.34 per share and provided FY2026 guidance.
Cinctive Capital Management LP Invests $3.97 Million in Teleflex Incorporated $TFX
Cinctive Capital Management LP recently purchased 32,423 shares of Teleflex Incorporated (NYSE:TFX) stock, valued at approximately $3.97 million, according to its latest SEC filing. This acquisition represents a new position for Cinctive Capital, and other institutional investors have also adjusted their holdings in Teleflex. The article also provides a financial overview of Teleflex, including stock performance, dividend information, and analyst ratings, noting that the medical technology company recently missed earnings estimates.
ArrowMark Colorado Holdings LLC Makes New $6.12 Million Investment in Teleflex Incorporated $TFX
ArrowMark Colorado Holdings LLC has made a new $6.12 million investment in Teleflex Incorporated (NYSE:TFX) by acquiring 50,000 shares in the third quarter. Other institutional investors have also significantly adjusted their positions in the medical technology company. Teleflex's stock performance and recent quarterly earnings are detailed, alongside a dividend announcement and updated analyst price targets.
917,925 Shares in Teleflex Incorporated $TFX Purchased by Abrams Bison Investments LLC
Abrams Bison Investments LLC has acquired 917,925 shares of Teleflex Incorporated (NYSE:TFX) worth approximately $112.3 million, making it their fourth-largest holding and comprising 8.8% of their portfolio. This purchase comes despite Teleflex reporting a weak quarter with lower-than-expected EPS and revenue, though the company provided optimistic FY2026 guidance. Teleflex currently has a "Hold" consensus rating from analysts with an average target price of $140.83.
o9 Announces Teleflex Global Go-Live for Integrated Demand and Supply Planning
o9 Solutions announced that Teleflex Incorporated has successfully implemented its AI-powered platform globally for Demand Planning and Supply Planning. This integration aims to enhance Teleflex's integrated business planning and supply chain management, improving coordination across teams, visibility into inventory and capacity, and alignment on trade-offs. The move is expected to boost forecast performance and overall supply chain resilience for the medical technology company.
How Teleflex’s new AI planning platform aims to cut back orders worldwide
Teleflex Incorporated has globally deployed o9's AI-powered platform for integrated demand and supply planning, aiming to enhance its business planning and supply chain management. This implementation connects demand forecasts and planning in a single environment, improving coordination, visibility, and decision-making for Teleflex. The company expects measurable improvements in forecast performance, inventory management, and a reduction in back orders, ultimately leading to more reliable service for healthcare professionals and patients.
Teleflex Inc. stock underperforms Tuesday when compared to competitors
Teleflex Inc. (TFX) stock fell 1.56% on Tuesday, closing at $111.84, while the broader market indices like the S&P 500 and Dow Jones also experienced declines. The company's stock is now 21.96% below its 52-week high of $143.32, which was reached on March 24th. This performance indicates an underperformance compared to the overall market on that specific trading day.
Teleflex Stock Review: Performance and Quality Assessment 2026 - News and Statistics
Teleflex's stock has declined over the past six months, reflecting concerns about the company's performance. Its long-term sales have decreased over five years, and the free cash flow margin is near zero, indicating weak demand and declining business quality. The company's valuation remains high despite these issues, suggesting better investment opportunities might exist elsewhere.
Teleflex Reports $1.99 Billion Revenue for 2025, Announces Restructuring
Teleflex Incorporated reported $1.99 billion in revenue for 2025, a 17.2% increase from the previous year, alongside GAAP diluted earnings per share of $1.31. The medical technology company announced a restructuring plan due to planned divestitures of three business units: Acute Care, Interventional Urology, and OEM, which are expected to close in the second half of 2026. This restructuring aims to optimize its portfolio, generate annual pre-tax savings of $48 million to $52 million by mid-2028, and use the estimated $1.8 billion in proceeds for share repurchases and debt reduction.
Q1 Earnings Estimate for Teleflex Issued By Wolfe Research
Wolfe Research has issued a Q1 2026 EPS estimate of $1.33 for Teleflex, projecting a multi-year recovery with FY2027 EPS of $12.19 rising to $17.14 by FY2030. This follows Teleflex's recent significant earnings and revenue miss in its latest quarterly report, and the company has set its own FY2026 guidance between $6.25 and $6.55 per share. Analyst sentiment for Teleflex is currently mixed, with a consensus "Hold" rating and a price target of $140.83, while the stock trades near $113.65.
Teleflex Incorporated $TFX Holdings Decreased by Citigroup Inc.
Citigroup Inc. significantly reduced its stake in Teleflex Incorporated (NYSE:TFX) by 40% in the third quarter, impacting its stock which opened down 3.3%. The medical technology company also reported disappointing quarterly earnings, missing analyst expectations for both EPS and revenue, and provided a cautious outlook for FY2026. Despite conflicting analyst ratings, the consensus remains a "Hold" with a target price of $140.83, and the company announced a quarterly dividend.
Teleflex (NYSE:TFX) Lowered to "Sell" Rating by Wall Street Zen
Teleflex (NYSE:TFX) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen. This follows a mixed bag of recent analyst reports, with some firms raising price targets and issuing "buy" ratings, while others like Zacks Research and Weiss Ratings have issued "sell" or "strong sell" ratings. The company recently missed earnings expectations for the last quarter and currently has an average target price of $140.83 among analysts.
[Form 4] TELEFLEX INC Insider Trading Activity
This Form 4 filing details insider trading activity at Teleflex Inc. for Corporate Vice President James Winters. It reports new equity awards, including stock options and restricted stock units granted under the company's 2023 Stock Incentive Plan, and a disposition of shares to cover tax obligations. The filing outlines vesting schedules for these awards and the resulting change in Winters' beneficial ownership.
